参麦注射液联合厄贝沙坦对腹膜透析患者微炎症状态及营养状态的影响  

Effect of Shenmai injection combined with irbesartan on the microinflammatory state and nutritional status of patients with peritoneal dialysis

作　　者：严小玲[1] 唐剑萍[1] 贺汉军 侯艾林[1] 张菘 

机构地区：[1]四川省广元市第一人民医院药学部,四川广元628000

出　　处：《海南医学院学报》2017年第21期2941-2944,2948,共5页Journal of Hainan Medical University

基　　金：广元市2013年科技技术项目编号:[2013]45~~

摘　　要：目的:研究参麦注射液联合厄贝沙坦对腹膜透析患者微炎症状态及营养状态的影响。方法:选择2014年5月-2016年11月期间在广元市第一人民医院接受腹膜透析的108例终末期肾脏病患者并随机分为两组,联合组接受参麦注射液联合厄贝沙坦治疗,ARB组接受厄贝沙坦治疗。治疗前及治疗后3个月、6个月时,检测两组患者的肾功能指标、炎症反应指标及营养状态指标。结果:两组患者组内治疗后3个月、6个月与治疗前Scr、BUN、RRF的比较无显著性差异;两组患者组内治疗后3个月、6个月与治疗前血清中SAA、CRP、PAPP-A、CHE、TNF-α、IL-6、IL-8含量的比较显著降低且联合组患者治疗后3个月、6个月与治疗前血清中SAA、CRP、PAPP-A、CHE、TNF-α、IL-6、IL-8含量与ARB组比较均显著降低;联合组组内治疗后3个月、6个月与治疗前血清中Alb、PA、Tf含量以及中臂肌围、中臂周径测量值的比较无显著性差异,对照组组内治疗后3个月、6个月与治疗前血清中Alb、PA、Tf含量以及中臂肌围、中臂周径测量值的比较显著降低。结论:参麦注射液联合厄贝沙坦用于腹膜透析能够减轻微炎症状态、改善营养状态。Objective:To study the effect of Shenmai injection combined with irbesartan on the microinflammatory state and nutritional status of patients with peritoneal dialysis.Methods:108 patients with end-stage renal disease who received peritoneal dialysis in Guangyuan First People's Hospital between May 2014 and November 2016 were selected and randomly divided into two groups,the combined group received Shenmai injection combined with irbesartan therapy,and the ARB group received irbesartan therapy.The renal function indicators,inflammatory response indicators and nutritional status indicators of the two groups were detected before treatment as well as 3 months and 6 months after treatment.Results:Scr,BUN and RRF of both groups 3 months and 6 months after treatment were not significantly different from those before treatment;serum SAA,CRP,PAPP-A,CHE,TNF-α,IL-6 and IL-8 contents of both groups 3 months and 6 months after treatment were significantly lower than those before treatment,and serum SAA,CRP,PAPP-A,CHE,TNF-α,IL-6 and IL-8 contents of combined group 3 months and 6 months after treatment were significantly lower than those of ARB group;serum Alb,PA and Tf contents as well as mid-arm muscle circumference and mid-arm circumference of combined group 3 months and 6 months after treatment were not significantly different from those before treatment while serum Alb,PA and Tf contents as well as mid-arm muscle circumference and mid-arm circumference of control group 3 months and 6 months after treatment were significantly lower than those before treatment.Conclusion:Shenmai injection combined with irbesartan for peritoneal dialysis can reduce the microinflammatory state and improve the nutritional status.

关 键 词：终末期肾脏病 腹膜透析 参麦注射液 厄贝沙坦 炎症反应 

分 类 号：R692[医药卫生—泌尿科学]